Skip to content

Evaluation of the Clinical Impact of Ultra Fast-Track in Patients Undergoing Cardiac Surgery

Evaluation of the Clinical Impact of Ultra Fast-Track in Patients Undergoing Cardiac Surgery Versus Conventional Extubation (CARDU-FAST)

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05706857
Acronym
CARDU-FAST
Enrollment
612
Registered
2023-01-31
Start date
2023-01-22
Completion date
2025-03-11
Last updated
2025-03-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anesthesia, Cardiac Disease, Surgery

Brief summary

Single center randomized clinical trial. The main aim is to demonstrate the superiority at the clinical level of the ultra fast-track programs versus conventional early postoperative extubation in patients undergoing cardiac surgery.

Detailed description

The study is aimed to compare clinical superiority of ultra fast-track versus conventional early postoperative extubation in patients undergoing cardiac surgery in our center. The estimated sample size is 612 patients. They will be randomized 1:1 to any of the two arms of the study (ultra fast-track vs. fast-track). The randomization will be stratified according the type of surgery performed. The period of recruitment will start in January 2023 and is supposed to finish by September 2024 or earlier. The main outcomes of the study will be measured 1 year after the procedure.

Interventions

BEHAVIORALUltra Fast-track

Patients are extubated in the operating room

Sponsors

Hospital San Carlos, Madrid
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
DOUBLE (Investigator, Outcomes Assessor)

Masking description

Double

Intervention model description

Randomized 1:1. Stratified by type of surgery (CABG, Valvular, Aorta)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients over 18 years of age. * Patients with valvular, coronary or aortic heart disease with an indication for major cardiac surgery. * The patient's desire to participate in the clinical trial verified by signing the informed consent.

Exclusion criteria

1. Pregnancy. 2. Emergent surgery or cardiorespiratory arrest. 3. Patient in preoperative cardiogenic shock, or in need of high-dose vasoactive support. 4. Aortic arch procedures. 5. Procedures in which hypothermia \< 28ºC of temperature is expected during the intervention. 6. Minor cardiac surgery procedures. 7. Procedures with minimally invasive techniques without extracorporeal circulation (Transcatheter aortic valve implantation, Transcatheter mitral valve implantation, Minimally invasive mitral valve repair (TOP-Mini), Totally thoracoscopic MAZE procedure, Minimally invasive direct coronary artery bypass grafting). 8. Implantation of circulatory assistance devices or ECMO (extracorporeal membrane oxygenation). 9. Active endocarditis.

Design outcomes

Primary

MeasureTime frameDescription
Determine the effect of Ultra Fast-track1 yearDetermine the effect of Ultra Fast-track on the occurrence of the composite outcome composed of all-cause mortality, respiratory complications (prolonged intubation over 24h, reintubation, or pneumonia) and AKIN-III (acute renal failure) in patients undergoing ultra fast-track and patients with conventional postoperative extubation.

Secondary

MeasureTime frameDescription
Differences in the need for high flow nasal oxygen therapy or non-invasive ventilation for >24h.1 yearComparison of the need for high flow nasal oxygen therapy or non-invasive ventilation for \>24h after the procedure.
Differences in major bleeding or life-threatening bleeding.1 yearComparison of the event of major bleeding or life-threatening bleeding (VARC 2 definition).
Differences in neurological complication1 yearComparison of the incidence of neurological complication after the procedure.
Procedural resources conpsumption1 yearComparison of operating room occupancy time (minutes), ICU stay and overall postoperative stay (days).
Differences in the incidence of heart reoperation1 yearComparison of the reoperation rate after the procedure.
Differences in the incidence of infections rate.1 yearComparison of the incidence of infection that requires intravenous antibiotic therapy, which causes an increase in hospital stay or engage patient's life.
Differences in the incidence of acute myocardial infarction.1 yearComparison of the incidence of acute myocardial infarction after the procedure.

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 29, 2026